SBRT Boost for Intermediate and High-Risk Prostate Cancer. Results of a single Chilean institution

被引：0
|
作者：
Sanchez, M. F. [1 ]
Bakal, F. [1 ]
Troncoso, A. [2 ]
Bettoli, P. [1 ]
机构：
[1] Fdn Arturo Lopez Perez, Dept Radiat Oncol, Santiago, Chile
[2] Univ Chile, Dept Tenol Med, Santiago, Chile
来源：
RADIOTHERAPY AND ONCOLOGY | 2022年 / 170卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1387
引用
收藏
页码：S1175 / S1176
页数：2
相关论文
共 50 条
  • [1] SBRT as Monotherapy or Boost for Intermediate or High-Risk Prostate Cancer: A Prospective Observational Study
    Hirsch, A.
    Ruffer, J. E.
    Green, L.
    Semanjaku, R.
    Asis, G.
    Kapinos, M.
    Rivelli, A.
    Liu, Y.
    Mohiuddin, M. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E279 - E279
  • [2] Outcomes of Hypofractionated SBRT Boost for Intermediate- and High-Risk Prostate Cancer: A Single Institutional Prospective Study
    Anwar, M.
    Weinberg, V.
    Hsu, I. J.
    Roach, M.
    Gottschalk, A. R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S105 - S106
  • [3] SBRT monotherapy for low and intermediate risk Prostate Cancer. First Chilean experience.
    Sanchez, M. F.
    Maza, F.
    Bakal, F.
    Bettoli, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1179 - S1180
  • [4] LDR-HDR boost in patients with intermediate-risk prostate cancer. A single Institution experience
    Rodriguez Villalba, S.
    Monasor Denia, P.
    Richart Sancho, J.
    Acosta Rojas, A.
    Perez-Calatayud, M. J.
    Perez-Calatayud, J.
    Santos Ortega, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S200 - S201
  • [5] Development of intermediate and high-risk prostate cancer after testicular cancer.
    Riggin, Andrew John
    Siddiqui, Mohummad Minhaj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.
    Muralidhar, Vinayak
    Xiang, MIchael H.
    Orio, Peter F.
    Martin, Neil E.
    Beard, Clair
    Feng, Felix Yi-Chung
    Hoffman, Karen E.
    Nguyen, Paul L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [8] Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
    Nicholls, Luke
    Suh, Yae-eun
    Chapman, Ewan
    Henderson, Daniel
    Jones, Caroline
    Morrison, Kirsty
    Sohaib, Aslam
    Taylor, Helen
    Tree, Alison
    van As, Nicholas
    [J]. CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 25 : 88 - 93
  • [9] Stereotactic body radiotherapy (SBRT) versus high dose rate (HDR) brachytherapy (BT) boost for high-risk (HR) prostate cancer.
    Gonzalez-Motta, Alejandro
    Roach, Mack
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] High-risk prostate cancer. Review
    Rozet, F.
    Hennequin, C.
    Fromont, G.
    Mongiat-Artus, P.
    Bastide, C.
    Beuzeboc, P.
    Cormier, L.
    Eiss, D.
    Peyrornaure, M.
    Richaud, P.
    Salomon, L.
    Soulie, M.
    [J]. PROGRES EN UROLOGIE, 2011, 21 (13): : 901 - 908
12345